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Background: Chronic kidney disease (CKD) and systemic inflammation are risk factors for sepsis. While often
viewed as a marker of chronic kidney disease, Cystatin C (Cyst-C) may also reflect systemic inflammation. We sought
to determine the association between elevated baseline Cyst-C and long-term rates of community-acquired sepsis,
and to determine if this relationship is influenced by traditional markers of CKD (estimated glomerular filtration rate
[eGFR], albumin-to-creatinine ratio [ACR]) and inflammation (high sensitivity C-reactive protein [hsCRP]).
Methods: We studied 30,239 adults ≥45 years old from the REasons for Geographic and Racial Differences in
Stroke (REGARDS) cohort. The primary exposure was elevated Cyst-C (>1.12 mg/dL) measured at study baseline. The
primary outcome was the first sepsis hospitalization during a 10-year observation period. Using Cox regression, we
evaluated the association between elevated Cyst-C and first sepsis event, adjusted for sociodemographics, health
behaviors, chronic medical conditions, eGFR, ACR and hsCRP.
Results: Among participants, 1,532 experienced a sepsis event. Median Cyst-C levels were: sepsis 1.08 (IQR 0.91-1.33)
mg/dL (43.8% >1.12 mg/dL), non-sepsis 0.94 (IQR 0.82-1.10) mg/dL (23.4% >1.12 mg/dL). Cyst-C > 1.12 mg/dL was
independently associated with increased rates of sepsis, adjusted for participant demographics, health behaviors and
chronic medical conditions (HR 1.75; 95% CI: 1.55-1.96). The addition of eGFR < 60 mg/min/1.73 m2, ACR≥ 30 mg/g
and hsCRP > 3.0 mg/dL only partially attenuated the association between Cyst-C > 1.12 mg/dL and rates of sepsis
(adjusted HR 1.51; 1.32-1.72).
Conclusions: Elevated Cyst-C is associated with increased long-term rates of community-acquired sepsis, independent
of abnormal eGFR, ACR or hsCRP. Cyst-C may play a role in long-term sepsis risk prediction and prevention.
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Sepsis is the syndrome of microbial infection compli-
cated by systemic inflammatory response. Sepsis is a
major public health problem in the United States (US),
encompassing 750,000 hospitalizations, 570,000 Emer-
gency Department visits and 200,000 deaths annually
[1-3]. The associated morbidity and mortality for sepsis
is substantial, with 28-50% dying from related complica-
tions [4]. While numerous studies highlight the physio-
logic response to and care of acute sepsis, relatively little
is known about risk factors that are associated with* Correspondence: hwang@uabmc.edu
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unless otherwise stated.increased long-term risk of sepsis [5-11]. Identification
of these risk factors could potentially lead to strategies
for preventing or limiting the impact of sepsis in these
individuals.
Cystatin C (Cyst-C) is a low molecular weight protein
that is produced by all nucleated cells and removed from
the bloodstream by glomerular filtration [12]. Cyst-C is
most commonly recognized as a marker of glomerular
function, with numerous studies evaluating its role in
detecting chronic kidney disease (CKD), acute kidney injury
and their associated sequelae [13-17]. However, studies of
cardiovascular disease, systemic lupus erythematosus and
malignancy highlight that Cyst-C may also act as a marker
of more generalized inflammation [15,16,18-23]. CKD and
inflammation are both associated with increased sepsis riskThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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evaluated the independent association of Cyst-C with future
sepsis risk [28,29].
In this study, we sought to determine the association




We used data from the Reasons for Geographic and Racial
Differences in Stroke (REGARDS) study, a national
population-based longitudinal cohort. This study was ap-
proved by the Institutional Review Board of the University
of Alabama at Birmingham. Written consent for participa-
tion was obtained by the parent REGARDS study.
Data source
REGARDS is one of the largest ongoing national cohorts of
community-dwelling adults in the US [30]. Created to
examine risk factors for stroke, REGARDS contains 30,239
community-dwelling adults aged ≥45 years. The cohort is
45% male, 41% African American, and 69% >60 years old.
The study oversampled black individuals and those living in
the Southeastern US, with 21% of the cohort originating
from the coastal plains of North Carolina, South Carolina
and Georgia (the “stroke buckle”), and 35% from the re-
mainder of North Carolina, South Carolina and Georgia
plus Tennessee, Mississippi, Alabama, Louisiana and
Arkansas (the “stroke belt”).
The REGARDS study recruited participants during
2003–2007. The study obtained baseline data for each
participant using both phone interview and in-person
evaluations. Baseline information included medical his-
tory, functional status, health behaviors, physical charac-
teristics (height, weight), physiologic measures (blood
pressure, pulse, electrocardiogram), and an inventory of
medications. Additional data included diet, family history
of diseases, psychosocial factors and prior residences. The
study also collected blood and urine specimens from
each participant.
Every 6 months, REGARDS contacted study participants
by telephone to identify the date, location and attributed
reason for all hospitalizations during the follow-up period.
Study personnel then retrieved medical records for
specific health events. If the participant died, the study
team reviewed death certificates and medical records and
interviewed proxies to ascertain the circumstances of
the death.
Outcomes - Identification of Sepsis Events
The primary outcome was a participant’s first
hospitalization for a sepsis event. Using a strategy devel-
oped by Angus et al., we identified hospital admissions
and emergency department visits attributed to a seriousinfection [3]. Trained abstractors reviewed relevant med-
ical records to confirm the presence of infection on ini-
tial hospital presentation and its relevance as a major
reason for hospitalization. Discordances were adjudi-
cated among abstractors, with additional physician re-
view as needed.
Consistent with international consensus definitions,
we defined sepsis events as hospitalization for infection
plus two or more systemic inflammatory response syn-
drome (SIRS) criteria. These include heart rate >90
beats/minute, fever (temperature >38.3°C or <36°C),
tachypnea (>20 breaths/min) or carbon dioxide partial
pressure (PCO2) <32 mmHg, and leukocytosis (white
blood cells >12,000 or <4,000 cells/mm3 or >10% band
forms) [2]. We determined vital signs and laboratory test
results for the initial 28-hours of hospitalization. Because
of our focus on “community-acquired” (vs. “hospital-ac-
quired”) sepsis, we did not include sepsis developing at
later points during hospitalization. We did not include
organ dysfunction in the definition of sepsis. Initial re-
view of 1,349 hospital records indicated excellent inter-
rater agreement for presence of serious infection (kappa
= 0.92) and the presence of sepsis (kappa = 0.90) upon
hospital presentation. We assessed sepsis events occur-
ring over a 10-year span from participant enrollment
through December 31, 2012.
Determination of Biomarker Levels
Study personnel collected blood and urine samples from
all REGARDS participants at subjects’ homes following a
10–12 hour fast. Samples were centrifuged to separate
serum or plasma within 2 hours of collection and shipped
overnight on ice packs to the laboratories at the University
of Vermont. On arrival, study personnel centrifuged the
samples at 30,000 g and 4°C. The samples were either ana-
lyzed (general chemistries) immediately or stored at −80°C.
Serum Cyst-C and hsCRP were assessed using particle-
enhanced immunonephelometry (N Latex Cystatin C, N
High-sensitivity CRP, Siemens AG, Munich, Germany). In
contrast with conventional CRP assays, the high-
sensitivity CRP technique is able to detect levels as low as
0.04 mg/L. Serum creatinine was determined by colori-
metric reflectance spectrophotometry (Ortho Vitros Clin-
ical Chemistry System 950IRC, Johnson & Johnson
Clinical Diagnostics, Raritan, New Jersey, USA). Urinary
albumin was measured via nephelometry (BN ProSpec
Nephelometer, Dade Behring, Siemens Healthcare,
Deerfield, Illinois, USA). Urinary creatinine was measured
with a rate blanked Jaffé procedure (Modular-P analyzer,
Roche/Hitachi, Roche Diagnostics, Indianapolis, Indiana,
USA). While not standardized to the International
Federation of Clinical Chemistry and Laboratory Medicine
(IFCC) standard, Cyst-C assay values were consistently
11% lower than the international benchmark.
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REGARDS determined participant characteristics during
the initial interview and in-home visit. Participant demo-
graphics included age, race, sex, income, educational at-
tainment, and geographic location. Race was defined as
white or black/African American. Income was divided
into four categories (<20,000$, 20–34,000$, 35–74,000$,
and ≥75,000$). Education categories included less than
high school, high school graduate, some college, college
or higher. Geographic region included the stroke “buckle”
(coastal plains of North Carolina, South Carolina and
Georgia), “stroke belt” (remainder of North Carolina,
South Carolina and Georgia plus Tennessee, Mississippi,
Alabama, Louisiana and Arkansas) and non-belt.
Health behaviors included tobacco and alcohol use.
Smoking status included current, past and never. We de-
fined alcohol use as moderate (1 drink per day for
women or 2 drinks per day for men) and heavy alcohol
use (>1 drink per day for women and >2 drinks per day
for men), per the National Institute on Alcohol Abuse
and Alcoholism classification [31].
Chronic medical conditions included cancer, coronary ar-
tery disease, diabetes, dyslipidemia, hypertension, myocar-
dial infarction, obesity and stroke. Participants self-reported
history of cancer, myocardial infarction or stroke. Coronary
artery disease included a history of myocardial infarction or
coronary intervention. Diabetes was defined as a fasting
glucose ≥126 mg/L (or a glucose ≥200 mg/L for those not
fasting) or the use of insulin or oral hypoglycemic agents.
Dyslipidemia consisted of low-density lipoprotein choles-
terol >130 mg/dL, or use of lipid lowering medications.
Hypertension included a systolic blood pressure ≥140 mm
Hg, diastolic blood pressure ≥90 mm Hg, or the reported
use of antihypertensive agents. Obesity included a body
mass index of ≥30 kg/m2 or waist circumference >102 cm
for males or >88 cm for females.
REGARDS did not collect information on pulmonary
conditions such as asthma and chronic obstructive pul-
monary disease. Therefore, we defined participant use of
pulmonary medications as a surrogate for chronic lung dis-
ease. Obtained from each participant’s medication inven-
tory, pulmonary medications included beta-2 adrenergic
agonists, leukotriene inhibitors, inhaled corticosteroids, com-
bination inhalers, and other pulmonary medications such as
ipratropium, cromolyn, aminophylline and theophylline.
Data Analysis
We defined elevated Cyst-C as serum levels above the
fourth quartile for the cohort (>1.12 mg/dL). We con-
verted serum creatinine to eGFR using the CKD-EPI
equation, defining eGFR levels <60 ml/min/1.73 m2 as
abnormal [32]. We similarly determined the ACR, de-
fining values ≥30 mg/g as abnormal. We defined
hsCRP >3.0 mg/dL as elevated [33].We compared demographic, health behavior and clin-
ical characteristics between participants with elevated
and normal Cyst-C utilizing Pearson chi-square or t-
tests. We defined person-time at risk as the time (days)
from first in-person examination to the first episode of
sepsis, the last follow-up interview, death or December
31, 2012, whichever came first. We censored all partici-
pants who died prior to the first sepsis event.
In evaluating the independent association of elevated
Cyst-C with first sepsis events, we first fit a series of Cox
regression models adjusting for participant demograph-
ics, health behaviors and chronic medical conditions. Be-
cause Cyst-C has been proposed as a marker of CKD,
incorporation of markers of CKD to the model would be
expected to attenuate the association between Cyst-C
and first sepsis event. Similarly, because Cyst-C is associ-
ated with systemic inflammation, incorporation of
hsCRP to the model would be expected to also reduce
the magnitude of the association between Cyst-C and
sepsis. Therefore, we sequentially added abnormal eGFR
and ACR, elevated hsCRP, and all three variables to the
multivariable model, evaluating the changes in the haz-
ard ratio for the association between Cyst-C and first
sepsis event. Due to a substantial number of missing
values for several variables (income 12.4%, Cyst-C 6.8%,
hsCRP 6.4%, albumin 4.7%, creatinine 4.5%), we per-
formed the multivariable modeling with multiple imput-
ation using chained equations (Stata “MI” suite), pooling
regression coefficient estimates for each model across 10
imputations using Rubin’s rules [34,35].
We verified the proportional hazards assumption
using scaled Schoenfeld residuals as well as examining
interactions with log-transformed study time. We ex-
amined multiplicative interactions between abnormal
Cyst-C, eGFR, ACR and hsCRP ([Cyst-C X eGFR],
[Cyst-C X ACR], [Cyst-C X hsCRP]) in the final model.
We verified the absence of collinearities by examining
variance inflation factors.
To test the robustness of the results, we conducted a
series of sensitivity analyses. We fit a model using Cyst-
C quartiles. In the primary analysis we defined eGFR,
ACR and hsCRP using cutoffs commonly used in clinical
practice; we repeated the analysis with eGFR, ACR and
hsCRP dichotomized to their 75th percentile values.
Lastly, we fit models with Cyst-C, eGFR, ACR and
hsCRP as continuous variables normalized by their re-
spective standard deviations.
We conducted all analyses using Stata 12.1 (Stata, Inc.,
College Station, Texas).
Results
Among the 30,239 REGARDS subjects, we included
29,696 participants with available follow-up information.
From February 5, 2003 through December 31, 2012
Figure 1 Kaplan-Meier Survival Curves for first-sepsis events, stratified by Cystatin C quartiles.
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encompassing 1,856 sepsis events among 1,532 individual
participants. Median follow-up time for each participant
was 6.6 years (interquartile range 5.1-8.1). Sepsis-free sur-
vival was lower among those with elevated Cyst-C than
those with normal Cyst-C (16.0 vs. 5.9 per 1000 person-
years). (Figure 1) The most common infection types asso-
ciated with the first sepsis episode were pneumonia
(39.4%), kidney and urinary tract infections (17.0%), and
abdominal infections (15.1 %) (Table 1).Table 1 Infection types associated with hospitalizations
for sepsis





Kidney and urinary tract infections 261 (17.0)
Abdominal 231 (15.1)
Bronchitis, influenza and other lung infections 138 (9.0)
Skin and soft tissue 123 (8.0)
Sepsis 104 (6.8)
Fever of unknown origin 29 (1.9)
Surgical Wound 10 (0.7)
Catheter (IV/Central/Dialysis) 6 (0.4)
Meningitis 5 (0.3)
Unknown/ther 22 (1.4)
Includes 1,532 first sepsis episodes.Median Cyst-C levels were 1.08 (IQR 0.91-1.33) mg/dL
for sepsis and 0.94 (IQR 0.82-1.10) mg/dL for non-sepsis
individuals (p < 0.001); 43.8% of sepsis and 23.4% of non-
sepsis individuals exhibited elevated Cyst-C >1.12 mg/dL.
The Pearson correlations between Cyst-C and eGFR, ACR
and hsCRP were −0.63, 0.35 and 0.15, respectively. Indi-
viduals with elevated Cyst-C were more likely to be older,
male and of white race (Table 2). Individuals with elevated
Cyst-C reported lower education and income levels. Ele-
vated Cyst-C was more common among past or current
smokers but less common among those with an alcohol
use history. Elevated Cyst-C was more common among
those with chronic medical conditions.
Following multiple imputation, in unadjusted analysis,
elevated Cyst-C (>1.12 mg/dL) was independently asso-
ciated with increased rates of sepsis (HR 2.70; 95% CI:
2.43-3.00) (Table 3). Elevated Cyst-C remained inde-
pendently associated with sepsis risk after adjustment
for sociodemographics, health behaviors and chronic
medical conditions (HR 1.75; 95% CI: 1.55-1.96). The as-
sociation between elevated Cyst-C and sepsis persisted
after adjusting for eGFR < 60 mg/min/1.73 m2 and
ACR ≥ 30 mg/g (HR 1.57; 95% CI: 1.38-1.79). Elevated
Cyst-C similarly remained independently associated with
sepsis after adjustment for hsCRP >3.0 mg/dL (HR 1.67;
95% CI: 1.48-1.87). Elevated Cyst-C also remained in-
dependently associated with sepsis after adjustment for
eGFR < 60 mg/min/1.73 m2, ACR ≥30 mg/g and hsCRP
>3.0 mg/dL (HR 1.51; 95% CI: 1.32-1.72).
The proportional hazards assumption was satisfied for
all covariates. The multiplicative interactions between
abnormal Cyst-C, eGFR, ACR and hsCRP ([Cyst-C X
Table 2 Characteristics of subjects by baseline Cystatin C quartiles
Characteristic Cyst-C Cyst-C Cyst-C Cyst-C p-value*
<0.83 mg/dL 0.83-0.94 mg/dL 0.95-1.12 mg/dL >1.12 mg/dL
(n=7,146) (n=6,732) (n=7,031) (n=6,757)
DEMOGRAPHICS
Age mean (SD) 59.8 (8.0) 63.3 (8.4) 66.2 (8.8) 70.3 (9.1) <0.001
Sex (%) <0.001
Male 59.1 45.9 48.8 46.6
Female 41.0 54.1 51.2 53.4
Race (%) <0.001
White 52.9 60.2 63.5 61.6
Black 47.1 39.8 36.6 38.5
Education (%)
Less than high school 8.8 10.2 12.8 17.4
High school graduate 23.6 24.8 26.3 28.7
Some college 26.3 27.0 27.0 27.0
College or higher 41.3 38.0 33.8 27.0
Missing N (%) 1 (0.0) 6 (0.1) 4 (0.1) 10 (0.2)
Income (%) <0.001
<$20 k 14.8 17.2 20.9 28.1
$20k-$34 k 22.8 25.3 28.5 33.7
$35k-$74 k 36.3 35.3 35.0 29.7
≥$75 k 26.2 22.2 15.6 8.5
Missing N (%) 812 (11.4) 795 (11.8) 882 (12.5) 879 (13.0)
Geographic region (%) 0.012
Non-belt/buckle 44.4 45.3 43.3 44.3
Stroke belt 35.4 33.6 36.1 34.0
Stroke buckle 20.2 21.1 20.6 21.8
HEALTH BEHAVIORS
Tobacco Use (%) <0.001
Current 12.9 14.5 15.1 15.4
Past 38.4 39.6 41.6 42.1
Never 48.7 45.9 43.3 42.5
Missing N (%) 33 (0.5) 24 (0.4) 25 (0.4) 19 (0.3)
Alcohol use (%) <0.001
Heavy 5.8 4.6 3.6 2.2
Moderate 40.1 36.3 32.2 25.4
None 54.1 59.1 64.2 72.5
Missing N (%) 134 (1.9) 124 (1.8) 128 (1.8) 157 (2.3)
CHRONIC MEDICAL CONDITIONS
Cancer (%) 6.2 7.4 9.5 12.1 <0.001
Chronic lung disease (%) 7.3 8.4 9.1 11.8 <0.001
Coronary artery disease (%) 10.2 13.3 18.1 30.2 <0.001
Diabetes (%) 17.4 18.1 20.5 33.1 <0.001
Dyslipidemia (%) 49.7 56.1 61.9 67.7 <0.001
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Table 2 Characteristics of subjects by baseline Cystatin C quartiles (Continued)
Hypertension (%) 45.8 52.7 61.5 76.8 <0.001
Myocardial infarction (%) 7.6 9.5 12.7 21.2 <0.001
Obesity (%) 43.7 50.2 56.1 62.9 <0.001
Stroke (%) 3.4 4.1 6.0 11.4 <0.001
BIOMARKERS
Serum creatinine-based estimated glomerular
filtration rate (eGFR) <60 mg/min/1.73m2 (%)
0.3 1.0 4.5 40.7 <0.001
Missing N (%) 6 (0.1) 7 (0.1) 6 (0.1) 11 (0.2)
Urinary albumin-to-creatinine ratio (ACR) ≥30 mg/g 9.0 9.4 12.7 29.7 <0.001
Missing N (%) 193 (2.7) 202 (3.0) 220 (3.1) 333 (4.9)
Serum high-sensitivity C-reactive protein (hsCRP) >3.0 mg/dL 31.9 36.3 42.9 51.8 <0.001
Missing N (%) 4 (0.1) 3 (0.4) 6 (0.1) 4 (0.1)
*Based on chi-square test for categorical variables and t-test for continuous variables. Based on 29,696 participants with follow-up data available. 2,030 (6.8%)
missing Cystatin C measurement.
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statistically significant. Based upon an examination of
variance inflation factors, there was no evidence of col-
linearity between Cyst-C and eGFR, ACR or hsCRP.
In sensitivity analyses, we repeated the effort using
quartiles of Cyst-C, the 75th percentile of eGFR
(<73.1 ml/min/1.73 m2), ACR (≥16.1 mg/g) and hsCRP
(>5.0 mg/dL), and continuous forms of Cyst-C, eGFR,
ACR and hsCRP normalized by their standard deviation
(Table 4). These models yielded inferences similar to the
primary analysis.
Discussion
CKD and systemic inflammation are recognized risk fac-
tors for sepsis [9-11]. While Cyst-C has been studied as a
marker of renal function, other studies highlight the po-
tential role of Cyst-C as a marker of more general systemic
inflammation [13,14,36,37]. In this analysis, elevated
serum Cyst-C > 1.12 mg/dL measured at baseline was in-
dependently associated with future risk of sepsis events.
This association persisted after adjusting for common
markers of CKD (abnormal creatinine-based eGFR and el-
evated ACR) as well as elevated hsCRP, a marker of sys-
temic inflammation [38]. These observations suggest that
Cyst-C may indicate the presence of additional steps in
the sepsis pathophysiological pathway that are not com-
pletely explained by renal disease or systemic inflamma-
tion. Our findings originate from REGARDS, one of the
largest population-based cohorts in the US and encompass
sepsis events over a 10-year span.
Recent attention has focused on the utility of serum
Cyst-C as a marker of renal disease, with studies indicat-
ing its superiority to serum creatinine for detecting pro-
gression to end-stage renal disease and mortality [14].
However, our observations support studies suggesting
that the health effects of Cyst-C are not entirelyexplained by renal function. For example, in a study of
8,058 persons in the Netherlands, Knight, et al. found
that older age, male gender, tobacco use and higher
weight, height and hsCRP were associated with Cyst-C,
independent of renal function [36]. In a study of 3,418
persons, Stevens, et al. found that factors other than
eGFR were associated with serum Cyst-C levels [37].
Other studies have characterized Cyst-C as a marker for
inflammation in cardiovascular disease, systemic lupus
erythematosus, and malignancy [15,16,18-23].
Select studies have evaluated elevated Cyst-C as a
proximal risk factor for sepsis. In a study of 444 inten-
sive care unit patients, Nejat, et al. found that elevated
urinary Cyst-C was associated with five-fold increased
adjusted odds of sepsis [28]. In a study of 5,142 subjects
≥65 years old in the Cardiovascular Health Study cohort,
Dalrymple et al. found that reduced eGFR estimated by
serum Cyst-C was associated with increased risk of
hospitalization for an infection [29]. Of note, the authors
found that eGFR calculated using serum creatinine did
not yield the similar associations, and comment that
Cyst-C may indicate additional factors beyond kidney
function that are associated with infection risk. Our com-
plementary study has important differences, including the
use of a broader age range of community-dwelling adults,
a longer follow-up period, Cyst-C measurements obtained
at stable phase of health, and focus on hospitalizations
for sepsis.
The utility of these findings is in aiding the prediction
of long-term sepsis risk. Sepsis is usually conceptualized
as an acute event, with current clinical and scientific ef-
forts focused on its early detection and management [2].
However, as is the case with conditions such as myocar-
dial infarction and stroke, prediction of sepsis risk at a
stable phase of health could have enormous impacts
upon its care and outcomes. For example, for individuals
Table 3 Hazard ratios (HRs) and 95% confidence intervals (CI) for the associations between elevated Cystatin C (Cyst-C >1.12 mg/dL) and rates of sepsis




Add eGFR and ACR Add hsCRP Add eGFR, ACR
and hsCRP
Cystatin C ≤1.12 mg/dL Referent Referent Referent Referent Referent Referent Referent
Cystatin C >1.12 mg/dL 2.70 (2.43-3.00) 2.12 (1.89-2.37) 2.06 (1.84-2.31) 1.75 (1.55-1.96) 1.57 (1.38-1.79) 1.67 (1.48-1.87) 1.51 (1.32-1.72)
eGFR≥60 ml/min/1.73m2 Referent Referent Referent
eGFR<60 ml/min/1.73m2 2.38 (2.10-2.70) — — — 1.13 (0.98-1.32) — 1.14 (0.98-1.32)
ACR <30 mg/g Referent Referent Referent
ACR ≥30 mg/g 2.22 (1.97-2.49) — — — 1.57 (1.38-1.79) — 1.45 (1.28-1.65)
hsCRP ≤3.0 mg/dL Referent Referent Referent
hsCRP >3.0 mg/dL 1.71 (1.54-1.90) — — — — 1.51 (1.35-1.68) 1.48 (1.32-1.65)
Estimates pooled after multiple imputation using Rubin’s rules, total of 29,696 REGARDS participants included in the analysis. *Age, sex, race, region, income, education. †Tobacco and alcohol use. ‡History of cancer,
chronic lung disease, coronary artery disease, diabetes, dyslipidemia, hypertension, myocardial infarction, obesity, stroke. eGFR = estimated glomerular filtration rate. ACR = albumin-to-creatinine ratio. hsCRP = high












Table 4 Sensitivity analysis
Variable Unadjusted Model 1 Model 2 Model 3 Model 4 Model 5
Cystatin C ≥1.12 mg/dL 2.70 (2.43-3.00) 1.51 (1.32-1.72) 1.60 (1.40-1.83)
Cystatin C Quartiles
Q1 (<0.83 mg/dL) Ref Ref Ref
Q2 (0.83-0.94 mg/dL) 1.40 (1.16-1.69) 1.14 (0.94-1.37) 1.14 (0.94-1.38)
Q3 (0.95-1.12 mg/dL) 1.81 (1.51-2.17) 1.20 (0.96-1.45) 1.22 (1.01-1.47)
Q4 (>1.12 mg/dL) 3.77 (3.20-4.45) 1.72 (1.42-2.09) 1.85 (1.51-2.27)
Cystatin C (per SD) (mg/dL) 1.24 (1.21-1.27) 1.16 (1.11-1.21)
eGFR <60 ml/min/1.73m2 2.38 (2.10-2.70) 1.14 (0.98-1.32) 1.14 (0.98-1.32)
ACR ≥30 mg/g 2.22 (1.97-2.49) 1.45 (1.28-1.65) 1.45 (1.28-1.65)
hsCRP >3.0 mg/dL 1.71 (1.54-1.90) 1.48 (1.32-1.65) 1.47 (1.31-1.64)
eGFR <73.1 ml/min/1.73m2 1.91 (1.72-2.12) 1.00 (0.87-1.14) 0.98 (0.86-1.12)
ACR ≥16.1 mg/g 2.05 (1.85-2.28) 1.41 (1.26-1.58) 1.41 (1.26-1.58)
hsCRP >5.0 mg/dL 1.75 (1.57-1.95) 1.51 (1.34-1.69) 1.49 (1.33-1.68)
eGFR (per SD) (ml/min/1.73m2) 0.69 (0.65-0.72) 0.97 (0.90-1.04)
ACR (per SD) (mg/g) 1.07 (1.03-1.11) 1.01 (0.97-1.06)
hsCRP (per SD) (mg/dL) 1.12 (1.10-1.15) 1.10 (1.06-1.14)
Hazard ratios (HRs) and 95% confidence intervals (CI) for the associations between Cystatin-C levels and rates of sepsis.
Estimates pooled after multiple imputation using Rubin’s rules. Total of 29,696 REGARDS participants included in the analysis. Except for unadjusted model, all models
adjusted for sociodemographics, health behaviors, and chronic medical conditions. eGFR = estimated glomerular filtration rate. ACR = albumin-to-creatinine ratio. hsCRP
= high sensitivity C-reactive protein. Cyst-C levels ranged from 0.1 to 11.9 mg/dL.
Model 1 – Primary model; binary Cyst-C; binary eGFR, ACR and hsCRP using clinical cutpoints.
Model 2 – Cyst-C quartiles; binary eGFR, ACR and hsCRP using clinical cutpoints.
Model 3 – Binary Cyst-C; binary eGFR, ACR and hsCRP using 75th percentile as cutpoints.
Model 4 – Cyst-C quartiles; binary eGFR, ACR and hsCRP using 75th percentile as cutpoints.
Model 5 – Continuous Cyst-C, eGFR, ACR and hsCRP, normalized by standard deviation.
Powell et al. BMC Nephrology  (2015) 16:61 Page 8 of 10identified as having the highest sepsis risk, clinicians
may implement more aggressive resuscitative care or
have a lower threshold for intensive care unit admission.
Our prior studies have identified a host of risk factors
associated with increased sepsis risk including chronic
kidney disease, chronic lung disease, obesity, increased
high-sensitivity C-reactive protein, and even physical in-
activity.[7-9,11]. While not formally evaluated in this
analysis, Cyst-C could offer additional risk prediction in-
formation. Further research is needed to better define
the role of Cyst-C in quantifying individuals’ long-term
sepsis risk.Limitations
Only Cyst-C measurements taken at baseline enrollment
in the REGARDS study were available for analysis. We
were unable to examine Cyst-C proximal to sepsis
hospitalization or repeat Cyst-C measurements. A portion
of subjects did not have Cyst-C measurements; we tried to
overcome this limitation through the use of multiple im-
putation. While Cyst-C levels were not standardized to
the IFCC standard, the application of a linear adjustment
would not have affected the observed inferences.REGARDS was designed to study stroke, not sepsis.
REGARDS is not a surveillance study, and thus we may
not have identified all sepsis events. However, misclassifi-
cation of sepsis events should be similar between Cyst-C
levels, and thus the analysis should present underestimates
of the true association. Early death may act as a competing
risk, preventing an individual from experiencing sepsis
events. Those with elevated Cyst-C exhibited higher rates
of death than those with normal Cyst-C; thus, we would
expect an even stronger association with sepsis risk if we
were to fully account for the competing risk of death.
By design, the REGARDS cohort includes only African
Americans and whites, and thus these results may not
generalize to other ethnic groups. We examined the
presence of comorbid conditions but not their severity.
The REGARDS cohort contains individuals over 45 years
old only; sepsis rates and the observed associations may
have differed for younger individuals. We identified indi-
viduals who presented to the hospital with sepsis, but
did not include those who acquired sepsis during their
hospitalization.
While we adjusted for a range of potential con-
founders, the observed associations may have been influ-
enced by other variables such as vaccination or access to
Powell et al. BMC Nephrology  (2015) 16:61 Page 9 of 10healthcare. As with all observational studies, residual con-
founding is always a concern. However, our risk adjust-
ment strategy accounted for a comprehensive range of
variables that were systematically identified for each par-
ticipant at the beginning of the REGARDS study. We
could not account for changes in these patterns over time.
Conclusion
In this study elevated serum Cyst-C measured at base-
line was independently associated with future risk of
sepsis. This association persisted event after adjustment
for markers of kidney disease and systemic inflamma-
tion. Cyst-C may play a potential role in sepsis risk pre-
diction and reduction.
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